<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04305769</url>
  </required_header>
  <id_info>
    <org_study_id>200046</org_study_id>
    <nct_id>NCT04305769</nct_id>
  </id_info>
  <brief_title>Alanyl-glutamine for CDI</brief_title>
  <official_title>Alanyl-glutamine Supplementation of Standard Treatment for C. Difficile Infection: A Randomized, Double-blind, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled trial to determine the optimal dose
      and safety of oral alanyl-glutamine between 4, 24, and 44 g doses administered for 10 days
      with standard therapy among first time incident cases of uncomplicated C. difficile infection
      (CDI) in hospitalized persons aged 65 or older. Our hypothesis is that alanyl-glutamine
      supplementation will decrease recurrence and mortality from CDI and these outcomes will be
      associated with improvement of inflammatory markers and restoration of intestinal microbiota
      function.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Block randomization will be applied to assign participants to one of the four study groups, either one of the three experimental (AQ) or control (placebo) group in 1:1:1:1 allocation from a list containing the randomized and blinded treatment assignments.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrent C. difficile infection</measure>
    <time_frame>Within 60 days post-treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Within 60 days post-treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Clostridioides Difficile Infection</condition>
  <condition>Clostridium Difficile Infection</condition>
  <condition>Clostridium Difficile Diarrhea</condition>
  <condition>Clostridia Difficile Colitis</condition>
  <arm_group>
    <arm_group_label>Alanyl-glutamine 0g</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Alanyl-glutamine 4g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Alanyl-glutamine 24g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Alanyl-glutamine 44g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alanyl-glutamine</intervention_name>
    <description>The study agent is AQ, a dipeptide with a glutamine amino group joined to an alanyl residue. It has the following chemical structure: C8H15N3O4. It is a non-animal product available in the form of white crystals or crystalline powder. It is odorless, tasteless, stable and highly soluble.</description>
    <arm_group_label>Alanyl-glutamine 0g</arm_group_label>
    <arm_group_label>Alanyl-glutamine 24g</arm_group_label>
    <arm_group_label>Alanyl-glutamine 44g</arm_group_label>
    <arm_group_label>Alanyl-glutamine 4g</arm_group_label>
    <other_name>Alagln</other_name>
    <other_name>AQ</other_name>
    <other_name>glutamine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of signed and dated informed consent form

          2. Stated willingness to comply with all study procedures and availability for the
             duration of the study

          3. Male or female, aged &gt; 65 years

          4. Admitted in the hospital

          5. Presence of diarrhea*

          6. Stool positive for C. difficile tcdB and TcdB

          7. 1st episode of C. difficile infection, non-severe or severe uncomplicated

          8. Within 48 hours of receiving standard therapy (oral vancomycin at UVA)

        Exclusion Criteria:

          1. At enrollment, presence of any of the following:

               -  Hypotension or shock

               -  Megacolon or moderate to severe ileus

               -  Acute abdomen

               -  Admission to intensive care unit

          2. Inability to tolerate oral or enteral medication

          3. Presence of other known infectious etiology of diarrhea

          4. Inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis) or other
             etiology of non-infectious diarrhea

          5. Enrollment in another investigational drug trial

          6. Current use of alternative treatment for CDI (e.g. antibiotics other than vancomycin
             or fidaxomicin; IVIg; fecal transplant).

          7. On probiotics and not willing to discontinue.

          8. Cirrhosis or in participants with ALT &gt; 3X normal

          9. End stage renal disease, on dialysis, or creatinine clearance or estimated GFR of
             &lt;30mL/min even after adequate hydration

         10. Life expectancy of &lt; 6 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>110 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 9, 2020</study_first_submitted>
  <study_first_submitted_qc>March 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2020</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Cirle Warren, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Clostridium Infections</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

